Loading...

BPMC BLUEPRINT MEDICINES CORP Product Launches 8-K Filing

BLPR

BPMC

BLUEPRINT MEDICINES CORP

(BPMC)

2023 8-K

Show Summary

Show Summary

Merger of Equals

Financial Statements

Financial Results

Corporate Update

Legal Validation

Q3 Financial Results

Earnings Reports

Annual Meeting and Stockhol...

Financing Agreement

Financial Results Announcement

Webinar on Mast Cell-Target...

Financial Results Announcement

Press Release and Corporate...

Earnings Reports

Withdrawal of U.S. indicati...

Annual Meeting of Stockholders

Financing Agreement Amendment

Earnings Reports

FDA Clinical Hold Lifted

Investor Conferences

Termination of Collaboratio...

Regulatory Action

Investor Conferences

Management Changes

External Links:

Blueprint Medicines Corp announces the voluntary withdrawal of the U.S. indication of GAVRETO for the treatment of RET-mutant medullary thyroid cancer (MTC) due to feasibility issues, with no impact on its collaboration revenue guidance.

AI Assistant

BLUEPRINT MEDICINES CORP

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.